Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission

References

• Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012;119:551–558.
   PubMed Web of Science ®Google Scholar
• Liersch R, Muller-Tidow C, Berdel WE, et al. Prognostic factors for acute myeloid leukaemia in adults—biological significance and clinical use. Br J Haematol 2014;165:17–38.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015;29: 312–320.
   PubMed Web of Science ®Google Scholar
• Ceze N, Thibault G, Goujon G, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 2011;68:1305–1313.
   PubMed Web of Science ®Google Scholar
• Vicente Conesa MA, Garcia-Martinez E, Gonzalez Billalabeitia E, et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast 2012; 21:468–474.
   PubMed Web of Science ®Google Scholar
• Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003;26: 394–402.
   PubMed Web of Science ®Google Scholar
• Williams KA, Labidi-Galy SI, Terry KL, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol 2014;132:542–550.
   PubMed Web of Science ®Google Scholar
• Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840–849.
   PubMed Web of Science ®Google Scholar
• Germing U, Strupp C, Aivado M, et al. New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002;100:731–732; author reply 2–3.
   PubMed Web of Science ®Google Scholar
• Beran M, Wen S, Shen Y, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007;48:1150–1160.
   PubMed Web of Science ®Google Scholar
• Le Jeune C, Bertoli S, Elhamri M, et al. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leuk Lymphoma 2014;55:855–862.
   PubMed Web of Science ®Google Scholar
• Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006;130:680–690.
   PubMed Web of Science ®Google Scholar
• Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005;124:170–181.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Siegler U, Kalberer CP, Nowbakht P, et al. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005;19:2215–2222.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051–3057.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014;123:3855–3863.
   PubMed Web of Science ®Google Scholar
• Buggins AG, Milojkovic D, Arno MJ, et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol 2001;167:6021–6030.
   PubMed Web of Science ®Google Scholar
• Orleans-Lindsay JK, Barber LD, Prentice HG, et al. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function—implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol 2001;126:403–411.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009;114:3793–3802.
   PubMed Web of Science ®Google Scholar
• Gasteiger G, Kastenmuller W. Foxp3 + Regulatory T-cells and IL-2: the Moirai of T-cell fates? Front Immunol 2012;3:179.
   PubMed Web of Science ®Google Scholar
• Ersvaer E, Liseth K, Skavland J, et al. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010;11:38.
   PubMedGoogle Scholar
• Wang X, Zheng J, Liu J, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005;75:468–476.
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325–3332.
   PubMed Web of Science ®Google Scholar
• Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011;129:1373–1381.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Hess AD, Gocke CD, et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood 2011;117:608–617.
   PubMed Web of Science ®Google Scholar